Please login to the form below

Not currently logged in
Email:
Password:

Plendil

This page shows the latest Plendil news and features for those working in and with pharma, biotech and healthcare.

AZ adds gout drug Zurampic to asset sale

AZ adds gout drug Zurampic to asset sale

Last month, AZ sold European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) -

Latest news

  • AZ offloads more products in slimming drive AZ offloads more products in slimming drive

    Will invest Moventig, Plendil and Imdur proceeds in its R&D pipeline. ... Meanwhile, earlier this week AZ also transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) - to China Medical

  • Update on AZ-Merck deal

    AZ will purchase rights to several Merck products, including the Crohn's Disease treatment Entocort, and blood pressure dugs Atacand, Lexxel and Plendil.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    $223m royalties. $142m. 1.6. Cardiovascular 2016. China Medical System. Plendil China.

  • Deal Watch February 2016 Deal Watch February 2016

    Being particularly active in out-licensing, AstraZeneca has granted a licence to China Medical System (CMS) in return for $310m to sell Plendil (felodipine), a calcium antagonist for hypertension in China. ... collaboration expanded. 500. AstraZeneca/

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics